J. Alan Butcher has been appointed executive vice president and chief business officer, AMAG Pharmaceuticals. He reports to William Heiden, president and chief executive officer.

Mr. Butcher is responsible for leading the company’s overall business development efforts, with a focus on continuing to expand the portfolio with products that address unmet patient needs. Additionally, he oversees the company’s alliance management team, and leads the corporate strategy function in close collaboration with Mr. Heiden, the senior leadership team, and the board of directors.

“I am very pleased to welcome Alan to AMAG’s senior leadership team. He joins us at an exciting time as we execute three product launches and prepare for an additional potential new product launch next year,” said William Heiden. “AMAG is well positioned to develop and commercialize new therapies for patients, and under Alan’s leadership, I’m confident that we will continue to remain focused on building a pipeline of products that will drive long-term growth, and create significant shareholder value.”

Mr. Butcher has extensive technical, scientific, strategic, and business development experience with his nearly two decades of corporate development work in large and medium-sized pharmaceutical companies. Most recently he served as senior vice president, licensing and business development for Purdue Pharma. Prior to Purdue, he led a global business development team and was responsible for identifying, evaluating and negotiating expansion opportunities at Shire Pharmaceuticals. Earlier in his career, Mr. Butcher conducted scientific research in areas of molecular genetics, virology and cardiovascular drug discovery.